Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201)

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Smee, Donald F ^a   Wong, Min Hui ^a   Russell, Andrew ^a   Ennis, Jane ^b   Turner, Jeffrey D ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b Defyrus Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CIDOFOVIR; DEF 201; PLACEBO; UNCLASSIFIED DRUG; CYTOSINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEATH; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HEPATITIS; IMMUNE RESPONSE; INFECTION PREVENTION; LUNG HEMORRHAGE; LUNG WEIGHT; NONHUMAN; PNEUMONIA; POST EXPOSURE PROPHYLAXIS; SPLEEN DISEASE; SURVIVAL; VACCINIA VIRUS; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INHIBITION; VIRUS TITRATION; WEIGHT REDUCTION; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; DRUG EFFECT; GENE VECTOR; GENETICS; INTRANASAL DRUG ADMINISTRATION; MOUSE; PATHOLOGY; PHYSIOLOGY; RESPIRATORY TRACT INFECTION; TIME; VACCINIA; VIROLOGY;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; MUS; VACCINIA VIRUS;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; BODY WEIGHT; CYTOSINE; FEMALE; GENETIC VECTORS; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; PHOSPHONIC ACIDS; PROTECTIVE AGENTS; RESPIRATORY TRACT INFECTIONS; SURVIVAL ANALYSIS; TIME FACTORS; VACCINIA; VACCINIA VIRUS;

EID: 80054058496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026330     Document Type: Article

References (21)

1. Bray M, (2003) Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 58: 101-114.
2. Smee DF, Sidwell RW, (2003) A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res 57: 41-52.
3. Smee DF, (2008) Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 19: 115-124.
4. Jahrling PB, Fritz EA, Hensley LE, (2005) Countermeasures to the bioterrorist threat of smallpox. Curr Mol Med 5: 817-826.
5. Lanier R, Trost L, Tippin T, Lampert B, Robertson A, et al. (2010) Development of CMX001 for the Treatment of Poxvirus Infections. Viruses 2: 2740-2762.
6. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, et al. (2009) ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother 53: 1817-1822.
7. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, et al. (2008) Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 46: 1555-1561.
8. Centers for Disease Control and Prevention (2009) Progressive vaccinia in a military smallpox vaccinee- United States, 2009. MMWR Morb Mortal Wkly Rep 58: 532-536.
9. Liu G, Zhai Q, Schaffner DJ, Wu A, Yohannes A, et al. (2004) Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. FEMS Immunol Med Microbiol 40: 201-206.
10. Newmann-Haefelin D, Sundmacher R, Sauter B, Karges HE, Manthey KF, (1975) Effect of human leukocyte interferon on vaccinia and herpes virus-infected cell cultures and monkey corneas. Infect Immun 12: 148-155.
11. Weimar W, Stitz L, Billiau A, Cantell K, Schellekens H, (1980) Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon. J Gen Virol 48: 25-30.
12. Perdiguero B, Esteban M, (2009) The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29: 581-598.
13. Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, et al. (1987) Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 27: 432-435.
14. Du Y, Tian H, Gao XD, Yao WB, (2008) Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-alpha (PEG-CIFN) in rhesus monkeys. Biopharm Drug Dispos 29: 481-484.
15. Hutson TE, Molto L, Mekhail T, Elson P, Finke J, et al. (2003) Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. Clin Cancer Res 9: 1354-1360.
16. Wu JQ, Barabe ND, Huang YM, Rayner GA, Christopher ME, et al. (2007) Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology 369: 206-213.
17. O'Brien L, Perkins S, Williams A, Eastaugh L, Phelps A, et al. (2009) Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J Gen Virol 90: 874-882.
18. Kumaki Y, Ennis J, Rahbar R, Turner JD, Wandersee MK, et al. (2011) Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral Res 89: 75-82.
19. Julander JG, Ennis J, Turner J, Morrey JD, (2011) Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob Agents Chemother 55: 2067-2073.
20. Smee DF, Bailey KW, Wong MH, Sidwell RW, (2001) Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res 52: 55-62.
21. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, et al. (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3: e3548.